891 related articles for article (PubMed ID: 15983224)
1. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
Meier JJ; Kemmeries G; Holst JJ; Nauck MA
Diabetes; 2005 Jul; 54(7):2212-8. PubMed ID: 15983224
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
[TBL] [Abstract][Full Text] [Related]
4. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
Nauck MA; Wollschläger D; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Willms B
Diabetologia; 1996 Dec; 39(12):1546-53. PubMed ID: 8960841
[TBL] [Abstract][Full Text] [Related]
5. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
[TBL] [Abstract][Full Text] [Related]
6. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.
Näslund E; Gutniak M; Skogar S; Rössner S; Hellström PM
Am J Clin Nutr; 1998 Sep; 68(3):525-30. PubMed ID: 9734726
[TBL] [Abstract][Full Text] [Related]
8. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
[TBL] [Abstract][Full Text] [Related]
9. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
[TBL] [Abstract][Full Text] [Related]
10. Effect of glucagon on carbohydrate-mediated secretion of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-36 amide) (GLP-1).
Ranganath L; Schaper F; Gama R; Morgan L; Wright J; Teale D; Marks V
Diabetes Metab Res Rev; 1999; 15(6):390-4. PubMed ID: 10634963
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM.
Dupre J; Behme MT; Hramiak IM; McFarlane P; Williamson MP; Zabel P; McDonald TJ
Diabetes; 1995 Jun; 44(6):626-30. PubMed ID: 7789625
[TBL] [Abstract][Full Text] [Related]
12. Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without type 2 diabetes.
Chowdhury S; Reeds DN; Crimmins DL; Patterson BW; Laciny E; Wang S; Tran HD; Griest TA; Rometo DA; Dunai J; Wallendorf MJ; Ladenson JH; Polonsky KS; Wice BM
Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G301-9. PubMed ID: 24356886
[TBL] [Abstract][Full Text] [Related]
13. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.
Meier JJ; Gethmann A; Nauck MA; Götze O; Schmitz F; Deacon CF; Gallwitz B; Schmidt WE; Holst JJ
Am J Physiol Endocrinol Metab; 2006 Jun; 290(6):E1118-23. PubMed ID: 16403774
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release.
Enç FY; Imeryüz N; Akin L; Turoğlu T; Dede F; Haklar G; Tekeşin N; Bekiroğlu N; Yeğen BC; Rehfeld JF; Holst JJ; Ulusoy NB
Am J Physiol Gastrointest Liver Physiol; 2001 Sep; 281(3):G752-63. PubMed ID: 11518688
[TBL] [Abstract][Full Text] [Related]
15. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans.
Nauck MA; Kemmeries G; Holst JJ; Meier JJ
Diabetes; 2011 May; 60(5):1561-5. PubMed ID: 21430088
[TBL] [Abstract][Full Text] [Related]
16. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.
Meier JJ; Nauck MA; Kranz D; Holst JJ; Deacon CF; Gaeckler D; Schmidt WE; Gallwitz B
Diabetes; 2004 Mar; 53(3):654-62. PubMed ID: 14988249
[TBL] [Abstract][Full Text] [Related]
17. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans.
Näslund E; Bogefors J; Skogar S; Grybäck P; Jacobsson H; Holst JJ; Hellström PM
Am J Physiol; 1999 Sep; 277(3):R910-6. PubMed ID: 10484511
[TBL] [Abstract][Full Text] [Related]
18. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
Nauck MA; Heimesaat MM; Behle K; Holst JJ; Nauck MS; Ritzel R; Hüfner M; Schmiegel WH
J Clin Endocrinol Metab; 2002 Mar; 87(3):1239-46. PubMed ID: 11889194
[TBL] [Abstract][Full Text] [Related]
19. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans.
Meier JJ; Goetze O; Anstipp J; Hagemann D; Holst JJ; Schmidt WE; Gallwitz B; Nauck MA
Am J Physiol Endocrinol Metab; 2004 Apr; 286(4):E621-5. PubMed ID: 14678954
[TBL] [Abstract][Full Text] [Related]
20. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.
Meier JJ; Gallwitz B; Salmen S; Goetze O; Holst JJ; Schmidt WE; Nauck MA
J Clin Endocrinol Metab; 2003 Jun; 88(6):2719-25. PubMed ID: 12788879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
